I-Mab (NASDAQ:IMAB) shares fell ~14% on Friday after the cancer drug developer announced a new “hub-and-spoke” business model, under which it plans to seek a name change and a potential dual listing ...
Less than two years after laying out plans to divest its China operations and become a U.S.-focused biotech, I-Mab Biopharma is re-staking its claim in the Asia-Pacific region. The drugmaker mapped ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback